LOGIN  |  REGISTER
Amneal Pharmaceuticals
Terns Pharmaceuticals

Mettler-Toledo to Host First Quarter 2023 Earnings Conference Call

April 10, 2023 | Last Trade: US$1,230.74 24.72 2.05

Columbus, OH, April 10, 2023 (GLOBE NEWSWIRE) -- Mettler-Toledo International Inc. (NYSE:MTD) today announced it will host a conference call to discuss the Company's quarterly results on Friday, May 5, 2023 at 8:30 a.m. Eastern Time. To hear a live webcast of the call, visit www.mt.com/investors on the Company's website.     

METTLER TOLEDO (NYSE: MTD) is a leading global supplier of precision instruments and services. We have strong leadership positions in all of our businesses and believe we hold global number-one market positions in most of them. We are recognized as an innovation leader and our solutions are critical in key R&D, quality control, and manufacturing processes for customers in a wide range of industries including life sciences, food, and chemicals. Our sales and service network is one of the most extensive in the industry. Our products are sold in more than 140 countries and we have a direct presence in approximately 40 countries. With proven growth strategies and a focus on execution, we have achieved a long-term track record of strong financial performance. For more information, please visit www.mt.com.

Assertio

Stock Quote

Last Trade: US$1,230.74
Daily Change: 24.72 2.05
Daily Volume: 219,381
Market Cap: US$25.970B

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB